Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial (Letter)

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Vergis, N
Phillips, R
Cornelius, V
Katsarou, A
Youngstein, T
Cook, L
Willicombe, M
Pilay, C
Shturova, T
Almonte, M
Charania, A
Turner, R
Kon, OM
Cooke, G
Thursz, M
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
Abstract

Objectives The primary objective of MATIS is to determine the efficacy of ruxolitinib (RUX) or fostamatinib (FOS) compared to standard of care (SOC) with respect to reducing the proportion of hospitalised patients progressing from mild or moderate to severe COVID-19 pneumonia.

Secondary objectives, at 14 and 28 days, are to:

Determine the efficacy of RUX or FOS to reduce mortality

Determine the efficacy of RUX or FOS to reduce the need for invasive ventilation or ECMO

Determine the efficacy of RUX or FOS to reduce the need for non-invasive ventilation

Determine the efficacy of RUX or FOS to reduce the proportion of participants suffering significant oxygen desaturation

Determine the efficacy of RUX or FOS to reduce the need for renal replacement therapy

Determine the efficacy of RUX and FOS to reduce the incidence of venous thromboembolism

Determine the efficacy of RUX and FOS to reduce the severity of COVID-19 pneumonia [graded by a 9-point modified WHO Ordinal Scale*

Determine the efficacy of RUX or FOS to reduce systemic inflammation

Determine the efficacy of RUX or FOS to the incidence of renal impairment

Determine the efficacy of RUX or FOS to reduce duration of hospital stay

Evaluate the safety of RUX and FOS for treatment of COVID-19 pneumonia. [...]

Journal Title

Trials

Conference Title
Book Title
Edition
Volume

22

Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© The Author(s). 2021 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Item Access Status
Note
Access the data
Related item(s)
Subject

Clinical sciences

Epidemiology

Health services and systems

COVID-19

coronavirus

fostamatinib

pneumonia

protocol

Persistent link to this record
Citation

Vergis, N; Phillips, R; Cornelius, V; Katsarou, A; Youngstein, T; Cook, L; Willicombe, M; Pilay, C; Shturova, T; Almonte, M; Charania, A; Turner, R; Kon, OM; Cooke, G; Thursz, M; et al., Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial, Trials, 2021, 22, pp. 270

Collections